Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Viltolarsen open-label extension in ambulant boys with Duchenne muscular dystrophy
NL-OMON51154Phase 3Recruiting
- Sponsor
- NS Pharma, Inc.
- Start
- Sep 2021
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of viltolarsen in Duchenne muscular dystrophy (DMD), sponsored by NS Pharma, Inc. Primary endpoints: Vital signs, Physical examination and 5 more. Started Sep 2021; status: recruiting.
02
Drugs
viltolarsen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NL-OMON51154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51154.